Investing News Network

Markets
TSX18618.54-215.62
TSXV598.85-17.09
DOW30907.94-59.88
S&P 5003829.17-2.22
NASD11314.24-8.00
ASX6629.30+16.70
Commodities
Gold1736.31-32.55
Silver19.19-0.03
Copper3.42+0.01
Palladium1916.50-11.50
Platinum854.50-10.50
Oil98.33-1.17
Heating Oil3.40-0.20
Natural Gas5.520.00
Currencies
BTCUSD20372.05+98.45
USDCAD1.3051+0.0017
USDEUR0.9816+0.0066
USDGBP0.8384+0.0015
USDAUD1.4744+0.0022
USDJPY135.73+0.21

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the position of Senior Vice President, Chief Financial Officer (CFO). In this role, Mr. Payne will lead Aptose's financial operations and serve as a member of the Company's executive management team.

"As a highly accomplished CFO, Fletcher brings to Aptose extensive experience in corporate finance, strategy and operations within the biotechnology industry, including the equity capital markets, banking practices and financial transaction experience," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. "We are delighted to have him join our executive management team and will benefit from his leadership, strategic insights, and guidance as we advance HM43239 and luxeptinib through clinical development toward commercialization."

Keep reading... Show less

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3

New "G3" Formulation of Luxeptinib Demonstrates Encouraging PK Results

Keep reading... Show less

Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3

New "G3" Formulation of Luxeptinib Demonstrates Encouraging PK Results

Keep reading... Show less
×